MA53688B1 - Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain - Google Patents
Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humainInfo
- Publication number
- MA53688B1 MA53688B1 MA53688A MA53688A MA53688B1 MA 53688 B1 MA53688 B1 MA 53688B1 MA 53688 A MA53688 A MA 53688A MA 53688 A MA53688 A MA 53688A MA 53688 B1 MA53688 B1 MA 53688B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibody
- human
- monoclonal antibodies
- trbv
- specifically bind
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2018146029A RU2711871C1 (ru) | 2018-12-25 | 2018-12-25 | Моноклональные антитела, которые специфически связываются с участком бета цепи семейства TRBV-9 Т-клеточного рецептора человека, и способы их применения |
PCT/RU2019/050257 WO2020139171A1 (ru) | 2018-12-25 | 2019-12-24 | Моноклональные антитела, специфически связывающиеся с trbv-9 человека |
Publications (2)
Publication Number | Publication Date |
---|---|
MA53688A1 MA53688A1 (fr) | 2022-06-30 |
MA53688B1 true MA53688B1 (fr) | 2023-03-31 |
Family
ID=69184146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53688A MA53688B1 (fr) | 2018-12-25 | 2019-12-24 | Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain |
Country Status (25)
Country | Link |
---|---|
US (1) | US20220056133A1 (zh) |
EP (1) | EP3904387A4 (zh) |
JP (1) | JP2022515820A (zh) |
KR (1) | KR20210118843A (zh) |
CN (1) | CN113692412A (zh) |
AR (1) | AR117735A1 (zh) |
AU (1) | AU2019416787A1 (zh) |
BR (1) | BR112021012550A2 (zh) |
CA (1) | CA3124800A1 (zh) |
CL (1) | CL2021001704A1 (zh) |
CO (1) | CO2021008204A2 (zh) |
CR (1) | CR20210353A (zh) |
EA (1) | EA202100199A1 (zh) |
EC (1) | ECSP21046332A (zh) |
IL (1) | IL284367A (zh) |
JO (1) | JOP20210168A1 (zh) |
MA (1) | MA53688B1 (zh) |
MX (1) | MX2021007718A (zh) |
PE (1) | PE20211792A1 (zh) |
PH (1) | PH12021551535A1 (zh) |
RU (1) | RU2711871C1 (zh) |
SG (1) | SG11202106974SA (zh) |
TW (1) | TW202033557A (zh) |
WO (1) | WO2020139171A1 (zh) |
ZA (1) | ZA202104356B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
CN116510006A (zh) * | 2022-01-31 | 2023-08-01 | 拜奥卡德联合股份公司 | 抗trbv9抗体的药物组合物及其用途 |
WO2024039268A1 (ru) * | 2022-08-18 | 2024-02-22 | Акционерное общество "БИОКАД" | Способ лечения заболевания, опосредованного т-лимфоцитами |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223426A (en) | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
US5766947A (en) | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
WO2004006955A1 (en) * | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
KR20120044941A (ko) * | 2009-06-25 | 2012-05-08 | 프레드 헛친슨 켄서 리서치 센터 | 적응 면역의 측정방법 |
US20130273089A1 (en) * | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
EP3202784A1 (en) * | 2016-02-08 | 2017-08-09 | Polybiocept AB | T-cell receptor sequences for active immunotherapy |
CA3042890A1 (en) * | 2016-11-14 | 2018-05-17 | Fred Hutchinson Cancer Research Center | High affinity merkel cell polyomavirus t antigen-specific tcrs and uses thereof |
JP7162607B2 (ja) * | 2017-02-27 | 2022-10-28 | 中外製薬株式会社 | 抗hla-dq2.5/8抗体およびセリアック病の治療のためのその使用 |
RU2694412C9 (ru) | 2017-12-25 | 2019-09-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Моноклональные антитела и способы их применения |
-
2018
- 2018-12-25 RU RU2018146029A patent/RU2711871C1/ru active
-
2019
- 2019-12-23 AR ARP190103841A patent/AR117735A1/es unknown
- 2019-12-24 US US17/417,570 patent/US20220056133A1/en active Pending
- 2019-12-24 EP EP19904442.1A patent/EP3904387A4/en active Pending
- 2019-12-24 CN CN201980092914.6A patent/CN113692412A/zh active Pending
- 2019-12-24 JP JP2021537704A patent/JP2022515820A/ja active Pending
- 2019-12-24 TW TW108147433A patent/TW202033557A/zh unknown
- 2019-12-24 EA EA202100199A patent/EA202100199A1/ru unknown
- 2019-12-24 SG SG11202106974SA patent/SG11202106974SA/en unknown
- 2019-12-24 WO PCT/RU2019/050257 patent/WO2020139171A1/ru unknown
- 2019-12-24 CA CA3124800A patent/CA3124800A1/en active Pending
- 2019-12-24 AU AU2019416787A patent/AU2019416787A1/en active Pending
- 2019-12-24 BR BR112021012550-7A patent/BR112021012550A2/pt unknown
- 2019-12-24 PE PE2021001079A patent/PE20211792A1/es unknown
- 2019-12-24 CR CR20210353A patent/CR20210353A/es unknown
- 2019-12-24 MA MA53688A patent/MA53688B1/fr unknown
- 2019-12-24 MX MX2021007718A patent/MX2021007718A/es unknown
- 2019-12-24 KR KR1020217023567A patent/KR20210118843A/ko unknown
- 2019-12-24 JO JOP/2021/0168A patent/JOP20210168A1/ar unknown
-
2021
- 2021-06-23 CO CONC2021/0008204A patent/CO2021008204A2/es unknown
- 2021-06-24 CL CL2021001704A patent/CL2021001704A1/es unknown
- 2021-06-24 ZA ZA2021/04356A patent/ZA202104356B/en unknown
- 2021-06-24 EC ECSENADI202146332A patent/ECSP21046332A/es unknown
- 2021-06-24 IL IL284367A patent/IL284367A/en unknown
- 2021-06-25 PH PH12021551535A patent/PH12021551535A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR117735A1 (es) | 2021-08-25 |
EA202100199A1 (ru) | 2021-12-02 |
ZA202104356B (en) | 2022-09-28 |
MA53688A1 (fr) | 2022-06-30 |
JP2022515820A (ja) | 2022-02-22 |
US20220056133A1 (en) | 2022-02-24 |
AU2019416787A1 (en) | 2021-08-12 |
KR20210118843A (ko) | 2021-10-01 |
PE20211792A1 (es) | 2021-09-09 |
SG11202106974SA (en) | 2021-07-29 |
RU2711871C1 (ru) | 2020-01-23 |
PH12021551535A1 (en) | 2022-02-28 |
CO2021008204A2 (es) | 2021-08-30 |
BR112021012550A2 (pt) | 2021-09-14 |
CL2021001704A1 (es) | 2022-01-28 |
MX2021007718A (es) | 2021-08-05 |
TW202033557A (zh) | 2020-09-16 |
IL284367A (en) | 2021-08-31 |
CA3124800A1 (en) | 2020-07-02 |
CN113692412A (zh) | 2021-11-23 |
CR20210353A (es) | 2021-12-20 |
EP3904387A1 (en) | 2021-11-03 |
ECSP21046332A (es) | 2021-07-30 |
JOP20210168A1 (ar) | 2023-01-30 |
EP3904387A4 (en) | 2022-09-07 |
WO2020139171A1 (ru) | 2020-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53688B1 (fr) | Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain | |
JP7244600B2 (ja) | 過リン酸化タウに特異的な抗体およびその使用方法 | |
AU2016292892B2 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
US10364286B2 (en) | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation | |
MA50128B1 (fr) | Anticorps monoclonaux liants le recepteur trbv9 des lymphocytes t et procédés de leur utilisation | |
JP2018531580A5 (zh) | ||
JP7331168B2 (ja) | 多発性骨髄腫におけるmタンパク質反応の臨床評価 | |
TWI678376B (zh) | 經改良之Aβ原纖維結合抗體 | |
MA31246B1 (fr) | Anticorps antagoniste d'ox40, et leur utilisation dans le traitement de maladies inflammatoires et auto-immunes | |
JP2898040B2 (ja) | gp130蛋白質に対する抗体 | |
CA3095443A1 (en) | Antibody-based methods of detecting and treating alzheimer's disease | |
MA53689A1 (fr) | Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application | |
EA202192606A1 (ru) | Антитела к пироглутамат--амилоиду и их применение | |
JPS6312297A (ja) | ヒトインタ−ロイキン−2−リセプタ−を認識するモノクロ−ナル抗体 | |
CN111518205B (zh) | 人源化抗Aβ单克隆抗体及其应用 | |
MA44917A1 (fr) | Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain. | |
Suzuki et al. | Idiotypic and fine specificity analysis of a (4‐hydroxy‐3‐nitrophenyl) acetyl (NP)‐specific suppressor T cell hybridoma at the level of cell surface structures, isolated receptor material and functional suppressor factor | |
Nishinarita et al. | IgA isotype-restricted idiotypes associated with T15 Id+ PC antibodies. | |
WO2024012434A1 (en) | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
Ramberger et al. | Synaptic autoimmunity: new insights into LGI1 antibody-mediated neuronal dysfunction | |
Poston et al. | Specific enzyme treatment is required for individual monoclonal antibodies in immunohistochemistry with formalin fixed sections | |
JP2017019755A (ja) | 標識免疫複合体を用いたアレルギー反応迅速識別法およびその誘導試薬キット | |
JP2020530901A (ja) | ミニブタ試料において抗薬物抗体を決定するための方法 | |
TW202413422A (zh) | 抗體、其抗原結合片段及其藥物用途 | |
WO2022015716A3 (en) | Novel anti-pd1 antibodies for inhibiting t-cell activity |